Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

To be able to join this study, people need to be at least 12 years old. They must have solid tumours that are advanced, meaning they have spread or haven't responded well to previous treatments. For those under 18, there's also a minimum weight requirement of 40 kg. Participants will need to have good general health, including healthy blood and organ function.

Doctors will also check specific features of your tumour using tests like tissue samples or blood tests. These tests look for certain changes in the cancer cells (like 'CCNE1 amplification', 'FBXW7 deleterious mutations', or 'PPP2R1A deleterious mutations') that suggest the treatment might be more likely to work. You need to be able to swallow medicines by mouth. If you have been on other treatments, you’ll need to have recovered from any side effects before starting this study.

There are also some reasons why someone might not be able to join. These include being pregnant or breastfeeding, having received certain cancer treatments too recently, or any other health condition that might make participating unsafe or complicate the study results. Your study doctor will review all your health information carefully to see if this study is right for you.

If you decide to take part in this study, you'll be given the study medication (lunresertib, either alone or with RP-3500 or Debio 0123) to take by mouth. You will have regular visits to the clinic for check-ups, which will involve physical examinations, blood tests, and scans to see how you are responding to the treatment and to monitor for any side effects. You'll need to answer questions about your health and how you are feeling. The exact number of visits and the duration of your participation will depend on how you respond to the treatment and the study plan, but you should expect frequent appointments. Your health will continue to be monitored even after you stop taking the study medication.